Back to search

Article

The Role of ERBB4 Mutations in the Prognosis of Advanced Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

2021-03-06

Abstract excerpt

<h4>Introduction: </h4> Recently, immune checkpoint inhibitors (ICIs) has been reported to achieved convincing clinical benefits and significantly prolonged the overall survival (OS) of advanced non-small cell lung cancer (NSCLC) patients. Sensitivity to immunotherapy was related to several biomarkers, such as PD-L1 expression, TMB level, MSI-H and MMR. However, novel biomarkers for the prognosis to ICIs treatment...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d6420d0a-1318-5d3c-b053-7ed500a8b45a
DOI
10.21203/rs.3.rs-281496/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Role of ERBB4 Mutations in the Prognosis of Advanced Non-small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsDOI 10.21203/rs.3.rs-281496/v1
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.Semantic proximity
PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer.Semantic proximity
Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.Semantic proximity
Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitorsSemantic proximity
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.Semantic proximity
Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity
Survival risk heterogeneity among patients with NSCLC receiving nivolumab visualized by risk scores generated from deep learning method DeepSurv using tumor gene mutationsSemantic proximity
B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitor for Lung AdenocarcinomaSemantic proximity
Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.Semantic proximity
Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity
Clinical and molecular characteristics, transcriptome, and drug efficacy of ERBB2 tyrosine kinase and non-tyrosine kinase mutations in non-small cell lung cancerSemantic proximity
Select a neighboring publication to make it the new centre.